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Introduction
Immune thrombocytopenic purpura (ITP) is an acquired au-
toimmune disorder involving antibody and cell mediated 
destruction of platelets. In acute cases the majority of pa-
tients have clinical bleeding and less than 30,000 platelets. 
Nowadays, there is enough evidence that immune destruc-
tion of circulating platelets and suppression of platelets 
production in the bone marrow is also happening.
Diagnosis is usually an easy task, requiring an isolated 
thrombocytopenia below 100×109/L, no other obvious cause 
for the condition and no clinically evident secondary form 
of immune thrombocytopenia.1,2 The incidence has geo-
graphic variation, but there are nearly 30 new cases per 
million annually, it is more prevalent in women and its inci-
dence increases with age.3 Over 70% of affected children 
resolve spontaneously, whereas ITP in adults is a more com-
plicated disease, typically having an insidious onset with no 
preceding viral or other illness and usually following a per-
sistent or chronic course.4
The stages of ITP according to the recent guidelines 
 include the following: a) acute ITP— months 0-3 after pre-
sentation; b) persistent ITP— 4-12 months; c) chronic ITP— 
>12 months; d) refractory ITP— patient without response to 
splenectomy, and e) severe ITP— patient has suffered major 
clinical bleeding.
Diagnosis
There is no special recommendation other than the exclu-
sion of an isolated cause of thrombocytopenia; in other 
words, there is not a “gold standard” test for ITP. I usually 
rule out HIV, hepatitis C, lupus, non-Hodgkin lymphoma, 
liver disease and Helycobacter pylori infection. 
It is very important to carefully review the blood smear in 
order to conirm the level of thrombocytopenia and rule out 
pseudo-thrombocytopenia and unexpected hematological 
diseases. The bone marrow is rarely studied in ITP, but it 
sometimes can be useful in selected elderly patients.
Treatment
In patients with thrombocytopenia of 30,000 or less, treat-
ment is usually indicated. Prednisone is the more common 
corticosteroid used as standard initial therapy. The dose is 
1-2 mg/kg per day for 2-4 weeks, and is given until a rise in 
the platelet count is obtained, which happens in about 75% 
of cases. However, many patients have a relapse when the 
dose of corticosteroids is reduced; only 5-30% will obtain a 
sustained remission.6-8 Splenectomy is considered the best 
option for patients suffering from chronic disease, but ap-
proximately 40% of splenectomized patients do not respond 
or relapse after surgery and are at risk of further infections.9 
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The thrombopoietin receptor agonists are truly “the new 
kids on the block” in the therapeutic armamentarium against 
ITP. Romiplostin and eltrombopag are both effective for 
chronic ITP, but they are dependent on continuous adminis-
tration and therefore both drugs are expensive, and its use 
in the patient suffering from the chronic form of the disease 
is not a realistic option in countries with economic problems 
belonging to the so called “underdeveloped” world.10,11
The role of high-dose dexamethasone in the treatment of 
acute ITP is not yet clariied, but pulses of this drug were 
effective as an initial therapy in 125 patients receiving 
40 mg/day for 4 consecutive days. In this study, a total of 
106 patients (85%) obtained a good initial response. Never-
theless, 50% relapsed within 6 months.12 Both prednisone in 
“low doses” daily for 2-4 weeks, and dexamethasone in 
“high doses” for 4 days once or twice in the irst month, are 
very good options. However, this lack of sustained response 
after stopping corticosteroids has prompted the search for a 
treatment able to modify both the underlying mechanism 
and the natural course of the disease. 
The use of high doses of intravenous IgG is very effective. 
I rarely use this option because the response only lasts 3-4 
weeks; 0.4 g/kg/day for 4 days is one way to administer the 
protein. Another effective way to give the drug is 1 g/kg in 
a single day. This drug, in combination with 40 mg of dexa-
methasone per day for 4 days, is indicated in patients with 
severe ITP.
Rituximab is a chimeric monoclonal antibody directed 
against CD20, an antigen expressed by mature B cells.13 It 
was approved and licensed in 1997 for the treatment of fol-
licular B cell lymphoma and has since been extensively stud-
ied in various autoimmune diseases such as rheumatoid 
arthritis, systemic lupus erythematosus, multiple sclerosis, 
acquired hemophilia, thrombotic thrombocytopenic purpu-
ra, autoimmune hemolytic anemia and ITP.14,15 Rituximab is 
generally administered at a dose approved for lymphomas 
(375 mg/m2 weekly for 4 weeks). However, the tumor bur-
den in lymphomas is often high, whereas in ITP the B cell 
mass is considered normal. Therefore, lower doses of ritux-
imab (100 mg/m2) have been used in the treatment of ITP, 
showing similar activity to the standard dose. It is important 
to note that rituximab is usually indicated in persistent or 
chronic cases, as a second line of therapy, and usually be-
fore splenectomy.16-21
New options in patients with ITP
In order to obtain a rapid and sustained response in ITP pa-
tients, we have used rituximab/dexamethasone or eltrom-
bopag plus dexamethasone as an initial therapy.22,23 Eligible 
patients for these prospective studies were ≥18 years old 
with newly-diagnosed ITP. Patients were excluded if they had 
an active bacterial or viral infection, HIV, HCV, or HBsAg posi-
tive serology, pregnancy or concomitant malignant disease.
Patients received dexamethasone at 40 mg/day for 4 con-
secutive days (+1, +2, +3, +4) and rituximab was adminis-
tered at a ixed dose of 100 mg as an IV infusion weekly for 
4 consecutive doses (days +1, +7+, +14 and +28). In the oth-
er study the patients received the same scheme of dexa-
methasone plus eltrombopag at 50 mg per day, from day 5, 
for 28 days. The results are encouraging, since 65 to 76% of 
patients obtained a sustained response. There is evidence 
that both rituximab and eltrombopag also have the capabil-
ity of modifying the T cell repertoire and the levels of 
T regs, improving the immune regulation. These studies 
showed promising results, however more studies are needed 
in order to conirm these preliminary observations. 
Conclusions
For more than 50 years, conventional therapy of ITP has in-
cluded corticosteroids as a front-line treatment. However, 
despite the high initial therapeutic eficacy, in most cases 
steroid tapering withdrawal is followed by a drop in platelet 
count and the need for additional treatment. Splenectomy 
is the most effective alternative in chronic cases, but ITP 
sometimes resolve spontaneously even in persistent cases, 
therefore I recommend to wait at least 12 months before 
the surgery. Rituximab is a very good alternative in order to 
obtain a longer and sustained response in persistent or 
chronic cases, and I usually use this drug before splenecto-
my. Conventional and lower doses of rituximab are effective 
in the majority of patients. On the other hand, there are 
several drugs used as a second or third line in the treatment 
of ITP: danazol, vinca-alcaloids, cyclophosphamide, azathi-
oprine, cyclosporine, etc., but eltrombopag and romiplostin 
are now considered the best options, if their high cost is not 
a problem. Finally, it is important to consider that danazol 
is a good alternative, it is also an inexpensive and safe oral 
drug, useful in chronic ITP, especially in cases where the 
thrombopoietin agonists are not available.
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